<DOC>
	<DOCNO>NCT02017626</DOCNO>
	<brief_summary>The aim study investigate safety tolerability Subcutaneous Immunotherapy treatment ( SCIT ) incremental dos modify recombinant fish parvalbumin ( mCyp c 1 ) quantify mass unit : To establish safe dose candidate hypo-allergen human subject To study pharmaco-dynamics hypo-allergen administered human subject . The study perform placebo-controlled double-blinded randomize trial 24 fish allergic patient allocate three different group eight .</brief_summary>
	<brief_title>FAST-Fish -Food Allergy Specific Treatment Fish Allergy .</brief_title>
	<detailed_description>The aim FAST project general develop novel recombinant allergen-based therapeutic treatment food allergy . The chosen approach modify recombinant allergens hypo-allergenic molecule decrease risk anaphylactic side-effects allow administration high dos lead good efficacy .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<criteria>Male female subject 18 65 year old general good health determine past medical history physical examination . Case history allergy fish ingestion . Specific IgE fish either positive SPT cod fish extract ImmunoCAP cod fish 0.70 kUA/L , ( Class 2 ) screening . Positive Double blind placebocontrolled Food challenge ( DBPCFC ) fish within last two year . FEV1 least 80 % predict value screen . Subject accept comply fully protocol . For woman child bear potential : negative urine pregnancy test screen visit , subject must receive medically effective contraceptive method study Food Anaphylactic Reaction : anaphylactic shock due fish intake . Specific IgE ( ImmunoCAP ) fish parvalbumin ( rCyp c 1 ) 0.35 kUA/L Ongoing pollen Immunotherapy ( SIT ) . Any clinical condition contraindicates SIT ( EAACIguidelines ) . Any significant clinical condition investigator judge might hamper patient 's safety study outcome , disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease , immunological endocrine disease . Ongoing treatment betablockers ACEinhibitors . Impossibility patient comply schedule visit . Pregnancy nursing . Uncontrolled asthma . Subject participate clinical trial within 3 month prior one . Subject history drug alcohol abuse . Investigators , coinvestigators , well child spouse study collaborator enrol study . Patients concurrent allergy symptom include patient manage without antihistamine screen treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Fish allergy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>hypoallergen</keyword>
</DOC>